On July 03, 2023, UK-based artificial biology firm Camena Bioscience introduced that it has closed a $10 million Series A financing spherical, which was led by Mercia, a UK-based enterprise capital agency. With the brand new funding, Camena intends to scale operations and proceed growing gSynth, its enzyme-based DNA synthesis platform.

According to an organization press launch, demand for DNA synthesis know-how has been rising as artificial genes are being extensively utilized in analysis to higher perceive the mechanisms of illness and within the drug discovery course of to fight illness. Cost, time, and accuracy of conventional DNA synthesis strategies (developed within the Nineteen Eighties) stays prohibitive, nevertheless, notably when creating lengthy or complicated sequences of genes. The know-how developed by Camena overcomes these limitations with using a novel enzymatic know-how that may precisely produce artificial DNA, in line with the press launch.

“We are delighted to have closed this latest round of funding with Mercia, which provides further validation of Camena’s approach. The ability to read, write, and manipulate DNA is the foundation of the synthetic biology value chain, yet developments in DNA synthesis have not kept pace with DNA sequencing and editing capabilities,” stated Steve Harvey, CEO, Camena, within the launch. “Camena’s gSynth platform is revolutionizing the DNA synthesis market by unlocking access to genes and accelerating discovery pipelines.”

“The invention of next-generation DNA sequencing technologies transformed our ability to ‘read’ DNA. Our goal is to enable our customers to ‘write’ DNA with the same confidence and ease,” Harvey added.

“The market for synthetic genes is growing rapidly, but much of the demand is for complex genes which are extremely difficult to produce accurately. Camena’s technology is a game changer that could unlock a much bigger global market. We’re excited to support Camena on its next stage of growth,” stated Lee Lindley, funding supervisor, Mercia, within the launch.

Source: Camena Bioscience